<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04984369</url>
  </required_header>
  <id_info>
    <org_study_id>HLX208-mCRC201（BECOMES）</org_study_id>
    <nct_id>NCT04984369</nct_id>
  </id_info>
  <brief_title>The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment</brief_title>
  <official_title>An Open, Multicenter Phase II Clinical Study to Evaluate Safety and Efficacy of HLX208 (BRAF V600E Inhibitor) Combined With Cetuximab in Patients With Metastatic Colorectal Cancer (mCRC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open, multicenter phase II clinical study to evaluate safety and efficacy of HLX208 (BRAF&#xD;
      V600E inhibitor) combined with cetuximab for metastatic colorectal cancer (mCRC) with BRAF&#xD;
      V600E Mutation after first-line treatment&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">August 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate(assessed by independent radiological review committee (IRRC) based on the RECIST Version 1.1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years]</time_frame>
    <description>Progression-free survival (PFS) (assessed by IRRC and the investigator as per RECIST v1.1 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose until the date of death from any cause，assessed up to 2 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>CRC</condition>
  <arm_group>
    <arm_group_label>Never use other BRAF inhibitor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Never use other BRAF inhibitor therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD after other BRAF inhibitor therapy N=5~40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD after other BRAF inhibitor therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SD but intolerant after other BRAF inhibitor therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SD but intolerant after other BRAF inhibitor therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX208</intervention_name>
    <description>HLX208 450mg bid po</description>
    <arm_group_label>Never use other BRAF inhibitor therapy</arm_group_label>
    <arm_group_label>PD after other BRAF inhibitor therapy N=5~40</arm_group_label>
    <arm_group_label>SD but intolerant after other BRAF inhibitor therapy</arm_group_label>
    <other_name>BRAF V600E inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab Injection [Erbitux]</intervention_name>
    <description>Cetuximab 500 mg/m2 IV Q2W</description>
    <arm_group_label>Never use other BRAF inhibitor therapy</arm_group_label>
    <arm_group_label>PD after other BRAF inhibitor therapy N=5~40</arm_group_label>
    <arm_group_label>SD but intolerant after other BRAF inhibitor therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;=18Y&#xD;
&#xD;
          -  Good Organ Function&#xD;
&#xD;
          -  Expected survival time ≥ 3 months&#xD;
&#xD;
          -  Metastatic/recurrent advanced BRAF+ mCRC that have been diagnosed histologically and&#xD;
             have failed first line treatment&#xD;
&#xD;
          -  ECOG score 0-1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  arm 1 ： Previous treatment with BRAF inhibitors or MEK inhibitors&#xD;
&#xD;
          -  Symptomatic brain or meningeal metastases (unless the patient has been on &gt; treatment&#xD;
             for 3 months, has no evidence of progress on imaging within 4 weeks prior to initial&#xD;
             administration, and tumor-related clinical symptoms are stable).&#xD;
&#xD;
          -  Active clinical severe infection;&#xD;
&#xD;
          -  A history of other malignancies within two years, except for cured carcinoma in situ&#xD;
             of the cervix or basal cell carcinoma of the skin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>junjie peng</last_name>
    <phone>86021-64175590</phone>
    <email>junjiepeng67@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Affiliated Oncology Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>junjie peng</last_name>
      <phone>021-64175590</phone>
      <email>junjiepeng67@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

